Stemtech (STEK) Debt to Equity (2013 - 2025)

Stemtech's (STEK) quarterly Debt to Equity came in at -$0.24 in Q4 2025, up 23.15% quarter-over-quarter from -$0.31 in Q1 2025.

Stemtech (STEK) Debt to Equity (2013 - 2025) Analysis & Trends

Stemtech has disclosed Debt to Equity across 6 years of filings, most recently posting -$0.24 for Q4 2025.

Debt to Equity for Q4 2025 came in at -$0.24, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was -$0.24 (changed N/A YoY), and the FY2025 annual result was -$0.24, changed N/A from the prior year.
Debt to Equity came in at -$0.24 for Q4 2025 at Stemtech, up from -$0.31 in the prior quarter.
In the past five years, Debt to Equity ranged from a high of -$0.24 in Q4 2025 to a low of -$1.46 in Q3 2023.
The 5-year median for Debt to Equity is -$0.65 (2022), against an average of -$0.7.
Peak annual rise in Debt to Equity reached 70.26% in 2023, while the deepest fall reached 99.96% in 2023.
Stemtech's Debt to Equity stood at -$1.11 in 2021, then rose by 22.78% to -$0.86 in 2022, then jumped by 32.92% to -$0.57 in 2023, then grew by 19.39% to -$0.46 in 2024, then surged by 48.85% to -$0.24 in 2025.
The last three Debt to Equity figures came in at -$0.24 (Q4 2025), -$0.31 (Q1 2025), and -$0.46 (Q2 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	2.02
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	2.80
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	-
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	0.01
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	-
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	0.61
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	0.86
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	-
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	0.47
10	Stemtech	-	-	354,677.00	-0.24

Download Data